BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

...S.A. (SIX:NESN).TARGETSIgE – Immunoglobulin E Paul Bonanos Palforzia, peanut allergen powder (AR101, arc001, peanut allergy oral immunotherapy (oit)) Nestle Health Science Nestle...
BioCentury | Aug 11, 2020
Product Development

Phase II learnings set up microbiome play Seres for Phase III success

Seres parlayed lessons learned from the failed Phase II trial of SER-109 to treat recurrent C. difficile infection into a Phase III win through improved patient selection and higher dosing. Seres Therapeutics Inc. (NASDAQ:MCRB) added...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year. Gurnet Point Capital...
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

$200M for Aimmune as it expands allergy pipeline Nestlé Health Science made a $200 million equity investment in Aimmune Therapeutics Inc. (NASDAQ:AIMT), giving it a 19.9% stake in the allergy company based on its outstanding...
BioCentury | Apr 12, 2019
Financial News

Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ. Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BioCentury | Nov 16, 2018
Financial News

Nestle invests $98M in Aimmune

...The Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN) will invest $98 million in Aimmune Therapeutics Inc. (NASDAQ:AIMT...
BioCentury | Oct 19, 2018
Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
Items per page:
1 - 10 of 60
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

...S.A. (SIX:NESN).TARGETSIgE – Immunoglobulin E Paul Bonanos Palforzia, peanut allergen powder (AR101, arc001, peanut allergy oral immunotherapy (oit)) Nestle Health Science Nestle...
BioCentury | Aug 11, 2020
Product Development

Phase II learnings set up microbiome play Seres for Phase III success

Seres parlayed lessons learned from the failed Phase II trial of SER-109 to treat recurrent C. difficile infection into a Phase III win through improved patient selection and higher dosing. Seres Therapeutics Inc. (NASDAQ:MCRB) added...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year. Gurnet Point Capital...
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

$200M for Aimmune as it expands allergy pipeline Nestlé Health Science made a $200 million equity investment in Aimmune Therapeutics Inc. (NASDAQ:AIMT), giving it a 19.9% stake in the allergy company based on its outstanding...
BioCentury | Apr 12, 2019
Financial News

Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ. Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BioCentury | Nov 16, 2018
Financial News

Nestle invests $98M in Aimmune

...The Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN) will invest $98 million in Aimmune Therapeutics Inc. (NASDAQ:AIMT...
BioCentury | Oct 19, 2018
Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
Items per page:
1 - 10 of 60